Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HE 2000

Drug Profile

HE 2000

Alternative Names: 16-Bromoepiandrosterone; Alpha-Epi-Br (HE2000) - Harbor BioSciences; Immunitin; Inactivin

Latest Information Update: 21 Feb 2012

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Colthurst
  • Developer Cystic Fibrosis Foundation Therapeutics; Harbor Therapeutics; Hollis-Eden Pharmaceuticals
  • Class Androstanols; Antivirals; Small molecules
  • Mechanism of Action Enzyme inhibitors; HIV replication inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Hepatitis B; Hepatitis C; HIV infections; Malaria; Tuberculosis
  • Discontinued Cystic fibrosis

Most Recent Events

  • 18 Jan 2011 HE 2000 licensed to China State Institute of Pharmaceutical Industry in China and Hong Kong
  • 06 Aug 2007 Suspended - Phase-II for Hepatitis B in Malaysia (unspecified route)
  • 06 Aug 2007 Suspended - Phase-II for Hepatitis B in Singapore (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top